Guillermo Montalban Bravo, M.D.

Abstracts

1. Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alavarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JC, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130(Suppl 1):2967, 2017.
2. Alfonso Pierola A, Assi R, KC D, Abaza Y, Abou Zahr A, Chamoun K, Montalban Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel KP, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood 130(Suppl 1 3852), 2017.
3. Naqvi K, Montalban Bravo G, Alfonso Pierola A, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, Gonzalez GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1 4258), 2017.
4. Jabbour EJ, Short NJ, Montalban Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes JE, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian HM, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130(No. 13):1514-1522, 2017.
5. Montalban Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian HM, Young KH, Garcia-Manero G, and Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(No. 18):2584-2587, 2017. e-Pub 2017.
6. Ana Alfonso Pierola, Guillermo Montalban-Bravo, Koichi Takahashi, Elias Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney Denton Dinardo, Naval Guastad Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero. Impact of the type of first-cancer therapy in therapy-related myelodysplastic syndromes outcomes. J Clin Oncol suppl(35), 2017.
7. Guillermo Montalban-Bravo, Ana Alfonso Pierola, Koichi Takahashi, Marina Konopleva, Elias Jabbour, Gautam Borthakur, Naval Guastad Daver, Courtney Denton Dinardo, Zeev Estrov, Tapan M. Kadia, Naveen Pemmaraju, Farhad Ravandi, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Keyur Patel, Guillermo Garcia-Manero. Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms with normal karyotype. J Clin Oncol suppl(35), 2017.
8. Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, Naval Guastad Daver, Farhad Ravandi, Gautam Borthakur, Koichi Takahashi, Michael Andreeff, Jorge E. Cortes, Courtney Denton Dinardo, Elias Jabbour, Tapan M. Kadia, Steven Kornblau, Maro Ohanian, Xuelin Huang, Graciela M. Nogueras-Gonzalez, Kristy Bodden, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero. Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. J Clin Oncol suppl(35), 2017.
9. Rita Elias Assi, Ana Alfonso Pierola, Devendra KC, Yasmin Mohammed Abaza, Abdallah Abou Zahr, Kamal Chamoun, Guillermo Montalban-Bravo, Koichi Takahashi, Elias Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney Denton Dinardo, Naval Guastad Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Andrew Futreal, Hagop M. Kantarjian, Guillermo Garcia-Manero, Sherry Pierce. Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). J Clin Oncol suppl(35), 2017.
10. Ganan-Gomez I, Alfonso A, Ogoti Y, Yang H, Montalban Bravo G, Yu AC, Marchesini M, Bueso-Ramos C, Takahashi K, Clise-Dwyer K, Garcia-Manero G, and Colla S. Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood 128(No. 22):4310, 2016.
11. Alfonso Pierola A, Marchesini M, Takahashi K, Ganan-Gomez I, Fiorini E, Ogoti Y, Irles E, Montalban Bravo G, Sofia S, Dwyer KC, Garcia-Manero G, and Colla S. The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood 128(No. 22):958, 2016.